Asset Details
Do you wish to reserve the book?
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
Do you wish to request the book?
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
2019
Overview
Thyroid cancer comprises different clinical and histological entities. Whereas differentiated (DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary (MTCs) tumors do not uptake radioactive iodine and display aggressive features associated with a poor prognosis. Moreover, in a majority of DTCs, disease evolution leads to the progressive loss of iodine sensitivity. Hence, iodine-refractory DTCs, along with ATCs and MTCs, require alternative treatments reflective of their different tumor biology. In the last decade, the molecular mechanisms promoting thyroid cancer development and progression have been extensively studied. This has led to a better understanding of the genomic landscape, displayed by thyroid malignancies, and to the identification of novel therapeutic targets. Indeed, several pharmacological compounds have been developed for iodine-refractory tumors, with four multi-target tyrosine kinase inhibitors already available for DTCs (sorafenib and lenvatinib) and MTCs (cabozantib and vandetanib), and a plethora of drugs currently being evaluated in clinical trials. In this review, we will describe the genomic alterations and biological processes intertwined with thyroid cancer development, also providing a thorough overview of targeted drugs already tested or under investigation for these tumors. Furthermore, given the existing preclinical evidence, we will briefly discuss the potential role of immunotherapy as an additional therapeutic strategy for the treatment of thyroid cancer.
Publisher
MDPI AG,MDPI
Subject
Antineoplastic Agents - therapeutic use
/ Disease
/ Genes
/ genome
/ Genomics
/ Humans
/ Iodine
/ Kinases
/ Mutation
/ Protein Kinase Inhibitors - therapeutic use
/ Proteins
/ Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
/ Receptor Protein-Tyrosine Kinases - genetics
/ Receptor Protein-Tyrosine Kinases - metabolism
/ Review
/ Thyroid Neoplasms - drug therapy
/ Thyroid Neoplasms - genetics
/ Thyroid Neoplasms - metabolism
/ Tumors
